Dietary Intervention for Cardiovascular Disease

Sponsor
Academia Sinica, Taiwan (Other)
Overall Status
Recruiting
CT.gov ID
NCT05201898
Collaborator
Taipei Veterans General Hospital, Taiwan (Other)
1,000
1
3
108.3
9.2

Study Details

Study Description

Brief Summary

Incidence of cardiometabolic disease (CMD) continues to rise, which consumes huge medical resources in Taiwan. The effectiveness of dietary therapy for CMD has not been locally evaluated in detail. CVD is an important risk factor for dementia. At the present time, there is no effective treatment available for dementia. Early prevention is extremely important. Our previous studies have shown that Taiwanese dementia protective diet is very similar to cardiovascular prevention and control diet, meaning that effective dietary therapy may not only control CVD but also prevent dementia development. Therefore, this study intends to document the effects of dietary intervention on cardiovascular disease risk factor control, the long-term outcomes on the occurrence of cardiovascular events, and the maintenance of cognitive function for patients with coronary artery disease.

Condition or Disease Intervention/Treatment Phase
  • Other: control:usual medical management
  • Behavioral: intervention 1:usual medical management+individual dieting consultation
  • Behavioral: intervention 2:usual medical management+individual dieting consultation+ daily tea drinking
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1000 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Dietary Intervention for Cardiovascular Disease
Actual Study Start Date :
Dec 23, 2021
Anticipated Primary Completion Date :
Dec 31, 2030
Anticipated Study Completion Date :
Dec 31, 2030

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: usual medical management

with regular doctor visits every 3 months

Other: control:usual medical management
with regular doctor visits every 3 months

Experimental: usual medical management+individual dietary consultation

with regular doctor visits every 3 months and dietitian visits every 3 months until meeting dietary recommendation or reaching 3 years limit

Other: control:usual medical management
with regular doctor visits every 3 months

Behavioral: intervention 1:usual medical management+individual dieting consultation
with regular doctor visits every 3 months and dietitian visits every 3 months

Experimental: usual medical management+individual dietary consultation+ daily tea drinking

with regular doctor visits every 3 months, dietitian visits every 3 months until meeting dietary recommendation or reaching 3 years limit, and daily tea drinking

Other: control:usual medical management
with regular doctor visits every 3 months

Behavioral: intervention 1:usual medical management+individual dieting consultation
with regular doctor visits every 3 months and dietitian visits every 3 months

Behavioral: intervention 2:usual medical management+individual dieting consultation+ daily tea drinking
with regular doctor visits every 3 months and dietitian visits every 3 months and daily tea drinking

Outcome Measures

Primary Outcome Measures

  1. Change from baseline in diet quality at Year 1, 2, and 3. [Baseline, year 1, 2 and 3]

    Diet quality is estimated according to the daily intake of nutrients and the distribution of the six food groups, with a qualified food frequency questionnaire. The six food groups include: Whole grains and starchy vegetables Protein foods: soybeans, fish, eggs, and meat Vegetables Fruits Dairy Oils, nuts & seeds

  2. Change from baseline in concentrations of cardiovascular risk factors at Month 6, 12, 18, 24,30, and 36. [Baseline and Month 6, 12, 18, 24, 30, and 36.]

    Cardiovascular risk factors include total cholesterol,triglyceride, low-density lipoprotein ,high-density lipoprotein, uric acid, glucose, HbA1C.

  3. Events of cardiovascular diseases at Year 6. [Year 6.]

    CVD or non-CVD death, stroke, acute myocardial infarction, hospitalization for acute coronary syndrome, hospitalization for coronary intervention surgery, hospitalization for various cardiovascular diseases, hospitalization for heart failure, hospitalization for other CVD diseases, new-onset heart arrhythmia, new-onset peripheral blood vessels block

Secondary Outcome Measures

  1. Change from baseline in the dosage of prescribed drugs at Month 6, 12, 18, 24,30, and 36. [Baseline and Month 6, 12, 18, 24, 30, and 36.]

    Prescribed drugs for cardiovascular diseases.

  2. Change from baseline in cardiovascular risk score [Baseline, year 1, 2 and 3.]

    Taiwanese edition of Framingham Risk Score, a 10-year risk score derived as a percentage. Risk is considered low if the Framingham Risk Score is less than 10%, moderate if it is 10% to 19%, and high if it is 20% or higher.

  3. Change from baseline in concentrations of inflammatory markers at Year 1, 2, and 3. [Baseline, year 1, 2 and 3.]

    Inflammatory markers include IL-1β, IL-6, IL-8, IL-10,TNF- α, IFN-γ in blood.

  4. Change from baseline in scores of Montreal Cognitive Assessment at Year 1, 2, and 3. [Baseline, year 1, 2 and 3.]

    Scores on the Montreal Cognitive Assessment range from zero to 30. A score of 26 and higher is considered normal.

  5. Change from baseline in scores of Number Cancellation test [Baseline, year 1, 2 and 3.]

    A sub-scale of Alzheimer's Disease Assessment Scale. Cancellation score = number of targets hit in 45 seconds - (minus) number of errors - (minus) number of times reminded of the task.

  6. Change from baseline in the number of digits at Year 1, 2 and 3. [Baseline, year 1, 2 and 3.]

    A digit span task is used to measure working memory's number storage capacity. Subjects are read a sequence of numbers and asked to repeat the same sequence back to the examiner in order (forward span) or in reverse order (backward span). The score is the length of the longest correctly repeated sequence. The maximum number of digits in a sequence is 9 and the minimum number of digits in a sequence is 2. The higher scores mean a better outcome.

Eligibility Criteria

Criteria

Ages Eligible for Study:
45 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Have received percutaneous transluminal coronary artery surgery.

  2. Stable drug control for more than one month

Exclusion Criteria:
  1. Suffer from cancer and undergo chemotherapy or surgery within one year.

  2. Those who have a major illness in hospital within one year.

  3. Those with kidney disease stage 5 (inclusive) or above

  4. Those whose life expectancy does not exceed half a year

  5. Patients with diagnosed dementia

  6. Those who do not want to be tracked

Contacts and Locations

Locations

Site City State Country Postal Code
1 Taipei Veterans General Hospital Taipei Beitou District Taiwan 112

Sponsors and Collaborators

  • Academia Sinica, Taiwan
  • Taipei Veterans General Hospital, Taiwan

Investigators

  • Principal Investigator: Wen-Harn Pan, Ph.D, Institute of Biomedical Sciences, Academia Sinica

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Wen-Harn Pan, Distinguished Research Fellow, Principal Investigator, Academia Sinica, Taiwan
ClinicalTrials.gov Identifier:
NCT05201898
Other Study ID Numbers:
  • AS-IRB-BM-19057
First Posted:
Jan 21, 2022
Last Update Posted:
Feb 3, 2022
Last Verified:
Jan 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 3, 2022